Clinical Trial Update: Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety of the CHK1 inhibitor VX-970 (M6620) in combination with whole-brain radiation therapy for brain metastases from lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Lung Neuroendocrine Tumor
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• VX-970 (M6620) (M6620)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-19